Gene expression patterns distinguish colonoscopically isolated human aberrant crypt foci from normal colonic mucosa

Cancer Epidemiology Biomarkers and Prevention

Volumn 15, Issue 11, 2006, Pages 2253-2262

  Glebov, Oleg K ^a   Rodriguez, Luz M ^a   Soballe, Peter ^b   DeNobile, John ^b   Cliatt, Janet ^a   Nakahara, Kenneth ^a   Kirsch, Ilan R ^a,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; INDIGO CARMINE; RNA; TUMOR MARKER;

ABERRANT CRYPT FOCI; ADULT; AGED; ARTICLE; ASCENDING COLON; CARCINOGENESIS; COLON BIOPSY; COLON MUCOSA; COLONOSCOPY; CONTROLLED STUDY; CRYPT CELL; DESCENDING COLON; DNA HYBRIDIZATION; DNA MICROARRAY; FEMALE; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; MALE; PRECANCER; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REG4 GENE; SRPN B5 GENE; TRIM29 GENE;

ADULT; AGED; BIOPSY; COLON; COLONIC NEOPLASMS; COLONOSCOPY; DNA, COMPLEMENTARY; FEMALE; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PRECANCEROUS CONDITIONS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 33845285904     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-05-0694     Document Type: Article

References (73)

1. Bird RP. Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett 1987;37:147-51.
2. Takahashi M, Wakabayashi K. Gene mutations and altered gene expression in azoxymethane-induced colon carcinogenesis in rodents. Cancer Sci 2004;95:475-80.
3. Bara J, Forgue-Lafitte ME, Maurin N, Flejou JF, Zimber A. Abnormal expression of gastric mucin in human and rat aberrant crypt foci during colon carcinogenesis. Tumour Biol 2003;24:109-15.
4. Canzian F, Ushijima T, Serikawa T, Wakabayashi K, Sugimura T, Nagao M. Instability of microsatellites in rat colon tumors induced by heterocyclic amines. Cancer Res 1994;54:6315-7.
5. Bird RP. Role of aberrant crypt foci in understanding the pathogenesis of colon cancer. Cancer Lett 1995;93:55-71.
6. Bird RP, Good CK. The significance of aberrant crypt foci in understanding the pathogenesis of colon cancer. Toxicol Lett 2000;112-113:395-402.
7. Li H, Schut HA, Conran P, et al. Prevention by aspirin and its combination with α-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon. Carcinogenesis 1999;20:425-30.
8. Pereira MA, Barnes LH, Steele VE, Kelloff GV, Lubet RA. Piroxicam-induced regression of azoxymethane-induced aberrant crypt foci and prevention of colon cancer in rats. Carcinogenesis 1996;17:373-6.
9. Rao CV, Hirose Y, Indranie C, Reddy BS. Modulation of experimental colon tumorigenesis by types and amounts of dietary fatty acids. Cancer Res 2001;61:1927-33.
10. Shpitz B, Klein E, Buklan G, et al. Suppressive effect of aspirin on aberrant crypt foci in patients with colorectal cancer. Gut 2003;52:1598-601.
11. Wargovich MJ, Jimenez A, McKee K, et al. Efficacy of potential chemopreventive agents on rat colon aberrant crypt formation and progression. Carcinogenesis 2000;21:1149-55.
12. Otori K, Sugiyama K, Hasebe T, Fukushima S, Esumi H. Emergence of adenomatous aberrant crypt foci (ACF) from hyperplastic ACF with concomitant increase in cell proliferation. Cancer Res 1995;55:4743-6.
13. Di Gregorio C, Losi L, Fante R, et al. Histology of aberrant crypt foci in the human colon. Histopathology 1997;30:328-34.
14. Fenoglio-Preiser CM, Noffsinger A. Aberrant crypt foci: a review. Toxicol Pathol 1999;27:632-42.
15. Roncucci L, Pedroni M, Fante R, Di Gregorio C, Ponz de Leon M. Cell kinetic evaluation of human colonic aberrant crypts. (Colorectal Cancer Study Group of the University of Modena and the Health Care District 16, Modena, Italy). Cancer Res 1993;53:3726-9.
16. Shpitz B, Bomstein Y, Mekori Y, et al. Proliferating cell nuclear antigen as a marker of cell kinetics in aberrant crypt foci, hyperplastic polyps, adenomas, and adenocarcinomas of the human colon. Am J Surg 1997;174:425-30.
17. Takayama T, Katsuki S, Takahashi Y, et al. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med 1998;339:1277-84.
18. Siu IM, Robinson DR, Schwartz S, et al. The identification of monoclonality in human aberrant crypt foci. Cancer Res 1999;59:63-6.
19. Sakurazawa N, Tanaka N, Onda M, Esumi H. Instability of X chromosome methylation in aberrant crypt foci of the human colon. Cancer Res 2000;60: 3165-9.
20. Roncucci L, Pedroni M, Vaccina F, Benatti P, Marzona L, De Pol A. Aberrant crypt foci in colorectal carcinogenesis. Cell and crypt dynamics. Cell Prolif 2000;33:1-18.
21. Renehan AG, O'Dwyer ST, Haboubi NJ, Potten CS. Early cellular events in colorectal carcinogenesis. Colorectal Dis 2002;4:76-89.
22. Mori H, Yamada Y, Kuno T, Hirose Y. Aberrant crypt foci and β-catenin accumulated crypts; significance and roles for colorectal carcinogenesis. Mutat Res 2004;566:191-208.
23. Smith AJ, Stern HS, Penner M, et al. Somatic APC and K-ras codon 12 mutations in aberrant crypt foci from human colons. Cancer Res 1994;54:5527-30.
24. Otori K, Konishi M, Sugiyama K, et al. Infrequent somatic mutation of the adenomatous polyposis coli gene in aberrant crypt foci of human colon tissue. Cancer 1998;83:896-900.
25. Beach R, Chan AO, Wu TT, et al. BRAF mutations in aberrant crypt foci and hyperplastic polyposis. Am J Pathol 2005;166:1069-75.
26. Luo L, Li B, Pretlow TP. DNA alterations in human aberrant crypt foci and colon cancers by random primed polymerase chain reaction. Cancer Res 2003;63:6166-9.
27. Chan AO, Broaddus RR, Houlihan PS, Issa JP, Hamilton SR, Rashid A. CpG island methylation in aberrant crypt foci of the colorectum. Am J Pathol 2002;160:1823-30.
28. Li H, Myeroff L, Smiraglia D, et al. SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. Proc Natl Acad Sci U S A 2003;100:8412-7.
29. Pretlow TP, Roukhadze EV, O'Riordan MA, Chan JC, Amini SB, Stellato TA. Carcinoembryonic antigen in human colonic aberrant crypt foci. Gastroenterology 1994;107:1719-25.
30. Hardy RG, Tselepis C, Hoyland J, et al. Aberrant P-cadherin expression is an early event in hyperplastic and dysplastic transformation in the colon. Gut 2002;50:513-9.
31. Wargovich MJ, Chang P, Velasco M, Sinicrope F, Eisenbrodt E, Sellin J. Expression of cellular adhesion proteins and abnormal glycoproteins in human aberrant crypt foci. Appl Immunohistochem Mol Morphol 2004;12:350-5.
32. Pretlow TP, O'Riordan MA, Pretlow TG, Stellato TA. Aberrant crypts in human colonic mucosa: putative preneoplastic lesions. J Cell Biochem Suppl 1992;15G:55-62.
33. Shpitz B, Bomstein Y, Mekori Y, et al. Aberrant crypt foci in human colons: distribution and histomorphologic characteristics. Hum Pathol 1998;29:469-75.
34. Nascimbeni R, Villanacci V, Mariani PP, et al. Aberrant crypt foci in the human colon: frequency and histologic patterns in patients with colorectal cancer or diverticular disease. Am J Surg Pathol 1999;23:1256-63.
35. Adler DG, Gostout CJ, Sorbi D, Burgart LJ, Wang L, Harmsen WS. Endoscopic identification and quantification of aberrant crypt foci in the human colon. Gastrointest Endosc 2002;56:657-62.
36. Hurlstone DP, Karajeh M, Sanders DS, Drew SK, Cross SS. Rectal aberrant crypt foci identified using high-magnification-chromoscopic colonoscopy: biomarkers for flat and depressed neoplasia. Am J Gastroenterol 2005;100:1283-9.
37. Rudolph RE, Dominitz JA, Lampe JW, et al. Risk factors for colorectal cancer in relation to number and size of aberrant crypt foci in humans. Cancer Epidemiol Biomarkers Prev 2005;14:605-8.
38. Roncucci L, Modica S, Pedroni M, et al. Aberrant crypt foci in patients with colorectal cancer. Br J Cancer 1998;77:2343-8.
39. Yamashita N, Minamoto T, Ochiai A, Onda M, Esumi H. Frequent and characteristic K-ras activation and absence of p53 protein accumulation in aberrant crypt foci of the colon. Gastroenterology 1995;108:434-40.
40. Moxon D, Raza M, Kenney R, et al. Relationship of aging and tobacco use with the development of aberrant crypt foci in a predominantly African-American population. Clin Gastroenterol Hepatol 2005;3:271-8.
41. Roncucci L, Stamp D, Medline A, Cullen JB, Bruce WR. Identification and quantification of aberrant crypt foci and microadenomas in the human colon. Hum Pathol 1991;22:287-94.
42. Bouzourene H, Chaubert P, Seelentag W, Bosman FT, Saraga E. Aberrant crypt foci in patients with neoplastic and nonneoplastic colonic disease. Hum Pathol 1999;30:66-71.
43. Niitsu Y, Takayama T, Miyanishi K, et al. Chemoprevention of colorectal cancer. Cancer Chemother Pharmacol 2004;54:S40-S43.
44. Takayama T, Miyanishi K, Hayashi T, et al. Aberrant crypt foci: detection, gene abnormalities, and clinical usefulness. Clin Gastroenterol Hepatol 2005;3:S42-5.
45. Glebov OK, Rodriguez LM, Nakahara K, et al. Distinguishing Right from Left Colon by the Pattern of Gene Expression. Cancer Epidemiol Biomarkers Prev 2003;12:755-62.
46. Van Gelder RN, von Zastrow ME, Yool A, Dement WC, Barchas JD, Eberwine JH. Amplified RNA synthesized from limited quantities of heterogeneous cDNA. Proc Natl Acad Sci U S A 1990;87:1663-7.
47. Simon R, Lam A. Brb-Arraytools user guide, version 3.2. Biometric Research Branch, National Cancer Institute. Available from: http://linus.nci. nih.gov/ brb. 2004.
48. Korn EL, McShane LM, Troendle JF, Rosenwald A, Simon R. Identifying prepost chemotherapy differences in gene expression in breast tumours: a statistical method appropriate for this aim. Br J Cancer 2002;86:1093-6.
49. Reiner A, Yekutieli D, Benjamini Y. Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics 2003;19:368-75.
50. Radmacher MD, McShane LM, Simon R. A paradigm for class prediction using gene expression profiles. J Comput Biol 2002;9:505-11.
51. Muller PY, Janovjak H, Miserez AR, Dobbie Z. Processing of gene expression data generated by quantitative real-time RT-PCR. Biotechniques 2002;32:1372-4, 1376, 1378-9.
52. Caderni G, Femia AP, Giannini A, et al. Identification of mucin-depleted foci in the unsectioned colon of azoxymethane-treated rats: correlation with carcinogenesis. Cancer Res 2003;63:2388-92.
53. Paulsen JE, Steffensen IL, Loberg EM, Husoy T, Namork E, Alexander J. Qualitative and quantitative relationship between dysplastic aberrant crypt foci and tumorigenesis in the Min/+ mouse colon. Cancer Res 2001;61:5010-5.
54. Pretlow TP, Bird RP. Correspondence Re: Y. Yamada Et Al., Frequent β-catenin gene mutations and accumulations of the protein in the putative preneoplastic lesions lacking macroscopic aberrant crypt foci appearance, in rat colon carcinogenesis. Cancer Res 2000;60:3323-7; and Sequential analysis of morphological and biological properties of β-catenin-accumulated crypts, provable premalignant lesions independent of aberrant crypt foci in rat colon carcinogenesis.
55. Cancer Res, 61:1874-1878, 2001.
56. Cancer Res 2001;61:7699-701.
57. Yamada Y, Mori H. Pre-cancerous lesions for colorectal cancers in rodents: a new concept. Carcinogenesis 2003;24:1015-9.
58. Yamada Y, Yoshimi N, Hirose Y, et al. Frequent β-catenin gene mutations and accumulations of the protein in the putative preneoplastic lesions lacking macroscopic aberrant crypt foci appearance, in rat colon carcinogenesis. Cancer Res 2000;60:3323-7.
59. Nambiar PR, Nakanishi M, Gupta R, et al. Genetic signatures of high- and low-risk aberrant crypt foci in a mouse model of sporadic colon cancer. Cancer Res 2004;64:6394-401.
60. Gokmen-Polar Y, Murray NR, Velasco MA, Gatalica Z, Fields AP. Elevated protein kinase C βII is an early promotive event in colon carcinogenesis. Cancer Res 2001;61:1375-81.
61. Xu MH, Deng CS, Zhu YQ, Lin J. Role of inducible nitric oxide synthase expression in aberrant crypt foci-adenoma-carcinoma sequence. World J Gastroenterol 2003;9:1246-50.
62. Stopera SA, Davie JR, Bird RP. Colonic aberrant crypt foci are associated with increased expression of c-fos: the possible role of modified c-fos expression in preneoplastic lesions in colon cancer. Carcinogenesis 1992;13:573-8.
63. Shpitz B, Bomstein Y, Shalev M, et al. Oncoprotein coexpression in human aberrant crypt foci and minute polypoid lesions of the large bowel. Anticancer Res 1999;19:3361-6.
64. Miyanishi K, Takayama T, Ohi M, et al. Glutathione S-transferase-π overexpression is closely associated with K-ras mutation during human colon carcinogenesis. Gastroenterology 2001;121:865-74.
65. Perrais M, Pigny P, Buisine M-P, Porchet N, Aubert J-P, Van Seuningen-Lempire I. Aberrant expression of human mucin gene Muc5b in gastric carcinoma and cancer cells. identification and regulation of a distal promoter. J Biol Chem 2001;276:15386-96.
66. Pinto-de-Sousa JJ, Reis CCA, David LL, Pimenta AA, Cardoso-de-Oliveira MM. Muc5b expression in gastric carcinoma: relationship with clinicopathological parameters and with expression of mucins Muc1, Muc2, Muc5ac and Muc6. Virchows Arch 2004;444:224-30.
67. Merrick BA, Madenspacher JH. Complementary gene and protein expression studies and integrative approaches in toxicogenomics. Toxicol Appl Pharmacol 2005;207:189-94.
68. Tian Q, Stepaniants SB, Mao M, et al. Integrated genomic and proteomic analyses of gene expression in mammalian cells. Mol Cell Proteomics 2004;3: 960-9.
69. Buecher B, Thouminot C, Menanteau J, et al. Fructooligosaccharide Associated with celecoxib reduces the number of aberrant crypt foci in the colon of rats. Reprod Nutr Dev 2003;43:347-56.
70. Brown WA, Skinner SA, Malcontenti-Wilson C, et al. Non-steroidal anti-inflammatory drugs with different cyclooxygenase inhibitory profiles that prevent aberrant crypt foci formation but vary in acute gastrotoxicity in a rat model. J Gastroenterol Hepatol 2000;15:1386-92.
71. Yamada Y, Yoshimi N, Hirose Y, et al. Suppression of Occurrence and Advancement of β-Catenin-Accumulated Crypts, Possible Premalignant Lesions of Colon Cancer, by Selective Cyclooxygenase-2 Inhibitor, Celecoxib. Jpn J Cancer Res 2001;92:617-23.
72. Rao CV, Indranie C, Simi B, Manning PT, Connor JR, Reddy BS. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Res 2002;62:165-70.
73. Glebov OK, Rodriguez LM, Lynch P, et al. Celecoxib treatment alters the gene expression profile of normal colonic mucosa. Cancer Epidemiol Biomarkers Prev 2006;15:1381-91.